Google DeepMind, Meta, and AI drug discovery company Isomorphic Labs are joining forces to support one of biomedical AI’s most ambitious goals: a digital model of life at the cellular level. The organizations are investing $300 million in Biohub, the nonprofit research institute founded by Mark Zuckerberg and Priscilla Chan.
The funding is part of a broader $1.8 billion virtual biology initiative focused on building AI-ready datasets that could let researchers “ask, predict, and answer” biological questions digitally. In practice, that means giving scientists new tools to simulate how cells behave, how diseases develop, and how potential treatments might work before moving into slower and more expensive lab experiments.
Why this matters
- Faster discovery: Digital biological models could help scientists test ideas more quickly.
- Better disease understanding: A “virtual cell” may reveal mechanisms that are difficult to observe directly.
- Stronger collaboration: The project brings together major AI labs, biomedical researchers, and nonprofit science funding.
While the technology is still developing, the scale of investment signals growing confidence that AI can meaningfully accelerate biomedical research. If successful, Biohub’s virtual cell work could become a powerful platform for discovering new ways to prevent, diagnose, and manage disease.